India's Alembic Pharma posts higher Q4 profit on strong N.America sales [Reuters]
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $80.00 to $81.00. They now have an "overweight" rating on the stock.
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow [Yahoo! Finance]